We analyzed the genomic and proteomic data from a recent integrated study of 99 glioblastomas (69) and found that YB-1 protein was enriched in the classical subtype, suggesting that a subset of patients with the classical subtype might have better clinical benefit from targeting YB-1. The gene discussed is YBX1; the disease is glioblastoma.